KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Non-cash Items (2016 - 2022)

Abbott Laboratories (ABT) has disclosed Non-cash Items for 14 consecutive years, with $23.5 million as the latest value for Q1 2022.

  • Quarterly Non-cash Items changed 0.12% to $23.5 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $23.5 million through Mar 2022, changed 0.12% year-over-year, with the annual reading at $2.1 billion for FY2021, 9983.01% up from the prior year.
  • Non-cash Items hit $23.5 million in Q1 2022 for Abbott Laboratories, down from $2.1 billion in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $2.1 billion in Q4 2021 to a low of $996.0 in Q4 2018.
  • Historically, Non-cash Items has averaged $550.3 million across 5 years, with a median of $23.5 million in 2021.
  • Biggest five-year swings in Non-cash Items: plummeted 100.0% in 2018 and later skyrocketed 114256928.11% in 2019.
  • Year by year, Non-cash Items stood at $996.0 in 2018, then surged by 114256928.11% to $1.1 billion in 2019, then surged by 36.82% to $1.6 billion in 2020, then surged by 32.05% to $2.1 billion in 2021, then plummeted by 98.85% to $23.5 million in 2022.
  • Business Quant data shows Non-cash Items for ABT at $23.5 million in Q1 2022, $2.1 billion in Q4 2021, and $22.7 million in Q3 2021.